You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 20, 2024

Investigational Drug Information for INCB054707


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug INCB054707?

INCB054707 is an investigational drug.

There have been 13 clinical trials for INCB054707. The most recent clinical trial was a Phase 2 trial, which was initiated on November 27th 2023.

The most common disease conditions in clinical trials are Hidradenitis Suppurativa, Hidradenitis, and Vitiligo. The leading clinical trial sponsors are Incyte Corporation, Incyte Biosciences Japan GK, and [disabled in preview].

There are fifteen US patents protecting this investigational drug and two hundred and thirteen international patents.

Recent Clinical Trials for INCB054707
TitleSponsorPhase
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)Incyte CorporationPhase 3
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)Incyte CorporationPhase 3
A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentIncyte CorporationPhase 1

See all INCB054707 clinical trials

Clinical Trial Summary for INCB054707

Top disease conditions for INCB054707
Top clinical trial sponsors for INCB054707

See all INCB054707 clinical trials

US Patents for INCB054707

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
INCB054707 ⤷  Sign Up Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
INCB054707 ⤷  Sign Up Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
INCB054707 ⤷  Sign Up Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
INCB054707 ⤷  Sign Up Heterocyclic compounds as PI3K-.gamma. inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
INCB054707 ⤷  Sign Up Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors Incyte Corporation (Wilmington, DE) ⤷  Sign Up
INCB054707 ⤷  Sign Up Crystalline forms of a PI3K inhibitor Incyte Corporation (Wilmington, DE) ⤷  Sign Up
INCB054707 ⤷  Sign Up Salts and processes of preparing a PI3K inhibitor Incyte Corporation (Wilmington, DE) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for INCB054707

Drugname Country Document Number Estimated Expiration Related US Patent
INCB054707 World Intellectual Property Organization (WIPO) WO2017027717 2035-08-12 ⤷  Sign Up
INCB054707 World Intellectual Property Organization (WIPO) WO2017035366 2035-08-26 ⤷  Sign Up
INCB054707 Australia AU2015244044 2034-04-08 ⤷  Sign Up
INCB054707 Australia AU2020213313 2034-04-08 ⤷  Sign Up
INCB054707 Australia AU2022206693 2034-04-08 ⤷  Sign Up
INCB054707 Brazil BR112016023322 2034-04-08 ⤷  Sign Up
INCB054707 Brazil BR122021024771 2034-04-08 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.